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ABSTRACT
Cancer immunotherapy with antibodies targeting immune checkpoints such as the PD-1/PD-L1 pathway
have emerged as breakthrough treatment for multiple solid tumors with high response rates and durable
remissions. Despite the beneﬁt for patients and encouraging safety proﬁle, severe inﬂammatory reactions
are observed in some patients. Such immune-related adverse events (irAEs) frequently lead to temporary
or permanent cessation of the treatment and require systemic immunosuppression yet underlying
mechanisms of irAEs are not known in detail. Here, we describe the T cell-mediated immune reaction in
irAE lesions of four patients that developed pneumonitis during therapy with a PD-1 blocking antibody.
Immunohistochemical analysis was performed to map the environment of the inﬂammatory lesions.
Tumor inﬁltrating T cell clones were identiﬁed by sequencing the T cell receptor, and comparison with
clones from peripheral blood or secondary lymphoid organs. A signiﬁcant overlap of clones inﬁltrating
irAE lesions and tumors was found. The most prevalent clones were also expanded in peripheral blood,
but only a minor fraction of clonal overlap was found. Our ﬁndings suggest that irAE lesions in patients
under PD-1 blockade are inﬁltrated by T cells with similar speciﬁcity as tumor-inﬁltrating T cells. These
results raise the possibility that the immune response is elicited in these patients against antigens shared
by the tumor and distant organs affected by irAEs.
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Introduction
Treatment of cancer patients with blocking antibodies that target
immune checkpoints including CTLA-4 or PD-1 and
PD-L1 lead to impressive response rates and, most notably, may
lead to durable remission in patients across different types of can-
cer.1–3 In particular, long-term beneﬁts have been observed in
patients with carcinogen-induced cancers and an increased muta-
tional load such as melanoma or tobacco-induced lung cancer.4
Positive results of randomized phase III trials have led to the
approval of antibodies blocking CTLA-4 and PD-1 or PD-L1 for
the treatment of melanoma, non-small cell lung cancer, bladder
cancer and squamous cell carcinoma of the head and neck.5–9 Var-
ious other indications are being tested in ongoing trials. Moreover,
the combination of PD-1 and CTLA-4 inhibitors has led to an
increase in response rates in patients with melanoma and is cur-
rently studied in different trials for other cancer types.5 In addi-
tion, many ongoing trials combine checkpoint blockade with
other immunotherapies or conventional anti-cancer treatment.2,10
Yet, while these data established immunotherapy as one of
the most promising clinical approaches to cancer treatment,
marked clinical response is observed in only a fraction of
patients, and is limited to cancers with multiple mutations and
high levels of expression of checkpoint molecules. Furthermore,
checkpoint blockade may entail severe inﬂammatory off-site
toxicity, so called immune-related adverse events (irAEs).11–14
These irAEs can be even life threatening and may involve vari-
ous organ systems including the skin, the gastrointestinal tract,
endocrine organs and the lung.11–14 Severe grade 3–4 irAEs are
found in about 22–24% of patients treated with the CTLA-4
inhibitor ipilimumab and in about 5–10% with PD-1 blocking
antibodies.11–14 Combination immunotherapy with PD-1 and
CTLA-4 inhibitors signiﬁcantly increases the rate of severe
inﬂammatory side effects to about 50 percent.5
The mechanisms that lead to loss of immune tolerance to
autoantigens and irAEs during checkpoint blockade are poorly
understood. In particular, it is unclear which patient will
develop clinically signiﬁcant side effects. Here, we report the
analysis of the T-cell repertoire diversity and clonal expansions
in four patients that developed irAEs during PD-1 blockade.
Results
Development of pneumonitis in patients during PD-1 blockade.
Adverse events leading to pulmonary lesions are seen in around
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1–2% of patients treated with PD-1 blocking agents.11,12 To fur-
ther analyze the T cell response in patients that developed pul-
monary toxicities, we identiﬁed four patients that underwent
PD-1 blockade and developed a histologically or cytologically
conﬁrmed inﬂammatory pneumonitis (Table 1). Three patients
had metastatic melanoma and one patient non-small cell lung
cancer (Table 1). All patients were treated with a PD-1 inhibitor
(either nivolumab or pembrolizumab). Two patients with mela-
noma had an objective response with one complete and one
good partial remission. One patient with melanoma had no
response to the treatment with disease progression. The patient
with an adenocarcinoma of the lung had a partial response to
PD-1 blockade. The time to the development of the irAEs varied
between three months and two years. Three patients had affec-
tion of a single organ with the development of anti-PD1 related
pneumonitis that radiologically and histologically presented as
an organizing pneumonia (Fig. 1). In one patient with mela-
noma and fatal tumor progression, immune toxicities were
detected only during necropsy and different organs including
the lung, the heart and the meninges were affected15 (Table 1).
Molecular analysis of the tumors was performed by a focused
next generation sequencing (NGS, OncoMine AmpliSeq Cancer
Hotspot Panel v2). Patient 1, 2 and 3 had a BRAF V600E muta-
tion. Also, the adenocarcinoma of patient 4 was studied by
focused NGS analysis and no mutation was detected in panel
tested. In all 3 patients with an objective response to PD-1 inhi-
bition, pneumonitis was controlled by treatment with corticoste-
roids and steroids were tapered over 4–6 weeks period.
Immunohistochemical analysis of T cell inﬁltrates. To com-
pare the immune inﬁltrates in irAE lesions to the tumor or
metastasis, we subjected the tissues of patient 1 and 2 to immu-
nohistochemical analysis with a special focus on markers of
T cell inﬁltration and T cell activation (Fig. 2A and 2B). We
had not enough tissue from patient 3 and 4 to perform the
extensive immunohistochemical analysis as for patient 1 and 2.
Quantiﬁcation and subtyping of T-cell inﬁltrates was carried
out by digital pathology methods (Figure S1). We observed a
similar inﬁltration of CD3 positive cells and higher CD4/CD8
ratios in the tumoral tissue compared to the corresponding
irAE lesions (Fig. 2B). Both CD4 and CD8 T cell inﬁltration
was increased in patient 1 in the tumor lesion compared to the
pulmonary irAE lesion, while in patient 2 more CD8 T cells
was seen in pneumonitis tissue (Fig. 2B). Also, activated CD8
T cells were increased in the irAEs (Fig. 2B, TIA1C cells), which
points towards an increased cytotoxic T cell response in these
lesions. We also stained for PD-1, PD-L1 and FoxP3 positive
cells in the tumor and in the irAE lesion (Fig. 1A, Table 2). In
particularly in patient 1, there was a strong presence of PD-L1
positive cells within the the pulmonary irAE tissue (Fig. 1A,
Table 2). However, the limited availability of tissue from all 4
patients for these markers prevents the inference of clear con-
clusions from this analysis and requires a larger number of
samples to be analyzed.
Overlap of T cell clonotypes in the tumor and irAE lesions. To
identify unique T cell clones we sequenced the complementary
determining region 3 (CDR) of the TCRb chain of irAE lesions
and compared it to tumor inﬁltrating lymphocytes (TILs). We
found a signiﬁcant overlap of T cell clones present in the irAEs
and corresponding tumor lesions in all the four patients
(Fig. 3). The most frequent T cell clones were identiﬁed in the
ﬁrst two patients in both the tumor and the irAE lesions and
represented the most prevalent clonotype (Fig. 3). The overlap
of sequences in patient 1 between the lung metastasis and irAE
lesion was signiﬁcantly higher when compared to overlaps with
T cell clones in the peripheral blood of this patient (Fig. 3A and
3E). We had several irAE lesions available from patient 2
(Fig. 3B). There was a variable proportion of shared T cell clo-
notypes between the primary tumor and the lung, meninges
and myocardium. The tumor tissue of patient 3 and 4 was lim-
ited and the analysis produced fewer sequences (Fig. 3C and
3D). Nevertheless, there was a clear overlap of clones found in
the pulmonary irAEs and in tumor tissue. Overall, the overlap
of the T cell repertoire in all patients was signiﬁcantly higher
between tumors and irAE lesions when compared to T cell
clones in the periphery or lymph node (Fig. 3E, Supplementary
Table S1).
Prevalent TIL and irAE lesion-inﬁltrating clones are circulat-
ing in the periphery. Recent analysis has shown that tumor-
Table 1. Characteristics of patients examined for the T cell response in tumor lesions and irAE lesions.
age (years) gender cancer treatment response immune-related adverse event
Patient 1 61 m melanoma pembrolizumab PR pneumonitis
Patient 2 35 f melanoma nivolumab PD multiple (pneumonitis, myocarditis, meningitis)
Patient 3 80 f melanoma pembrolizumab CR pneumonitis
Patient 4 71 m NSCLC pembrolizumab PR pneumonitis
PR, partial response; PD, progressive disease; CR, complete response.
Figure 1. Development of pneumonitis during PD-1 blockade. (A, B) An FDG-posi-
tive pulmonary lesion of patient 1 (A) was resected and presented as organizing
pnmeumonia in the histological examination (B). (C, D) An FDG-negative lesion in
the same patient was resected (C) and a necrotic melanoma metastasis was found
by histological analysis (D).
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reactive clones can be found in the periphery.16 We therefore
wanted to test if frequent T cell clones in irAE lesions could
also be found in the periphery. Analysis and comparison of the
frequency of T cell clones of tumor lesions and irAE lesions
was performed to study if common and potentially relevant
clones can be found in the peripheral blood or also secondary
lymphoid organs (lymph node). In patient 1, we detected the
most prevalent clones in the metastatic lesion, the pulmonary
irAE lesion but also in the peripheral blood (Fig. 4A and 4B).
Similarly, several prevalent clones found in the tumor were also
detected in secondary lymphoid organs of patient 2 including
the lymph node (Fig. 4C and 4D).
Discussion
Our report is the ﬁrst analysis of the TCR repertoire in pulmo-
nary inﬂammatory lesions from patients treated with PD1
inhibitors. We demonstrate a signiﬁcant overlap of the T cell
repertoire in irAE lesions and TILs. This underlines that the
most frequent T cell clones in the tumor and irAEs are shared.
In support of this a recent report of two patients with fatal
myocarditis identiﬁed a strong expression of muscle-associated
proteins including troponin and desmin in the tumor.17 Our
data support a similar possibility, i.e. that T cells in our patients
react to shared antigens that can be found in the tumor and
also in the lung. Bioinformatical approaches have recently been
published that could allow antigen determination by sequenc-
ing the TCR by two independent groups.18,19 Using such meth-
odology, the antigens of prevalent clones in tumors and also in
irAE lesions could be potentially deﬁned. Recent studies have
also shown an expansion of autoreactive T cell clones in the
periphery upon treatment with CTLA-4 blocking antibodies in
patients with prostate cancer.20 Not only an expansion of clones
was seen but also a diversiﬁcation of T cells was detected in
prostate cancer patients treated with CTLA-4 blocking antibod-
ies and experiencing irAEs21, which supports the hypothesis
that newly developed reactivity to shared auto-antigens may
play role in the generation of inﬂammatory complications in
patients undergoing checkpoint blockade. An important ques-
tion with regard to shared antigens is if identiﬁed frequent
clones that are most likely tumor-reactive are causative for
irAE lesions or inﬂammation in target organs of irAEs driven
by other T cell clones attracts tumor speciﬁc T cells into these
organs as a non-speciﬁc secondary event. These activated
tumor-speciﬁc T cells may then further augment the initial
local inﬂammation.
In general, the exact mechanism of how irAEs in patients
treated with checkpoint blockade develop remains largely
unknown.22 Other potential mechanisms of irAE development
include an exacerbation of previous subclinical autoimmune
syndromes, which would be revealed by lowering the threshold
for immune activation by the treatment with checkpoint inhibi-
tors.23,24 In one case, a patient who developed severe myositis
upon treatment with nivolumab and ipilimumab had pre-exist-
ing anti-striated muscle antibodies.23 In another case, a patient
with metastatic NSCLC developed a cerebral vasculitis with
pre-existing anti-nuclear antibodies (ANAs) and anti-endothe-
lial antibodies.24 However, larger cohorts have not yet been
analyzed and it remains unknown if screening for autoantibod-
ies could be used as a biomarker to identify patients at risk for
irAEs. An early phase trial with anti-CTLA-4 blocking antibod-
ies showed also a dependence of irAE development on
polymorphisms of the CTLA-4 gene.25 Treatment with check-
point inhibitors including CTLA-4 blocking antibodies can
Figure 2. Histological analysis of tumor and irAE-inﬁltrating T cells. (A) Representative images of IHC analysis of the pulmonary irAE lesion from patient 1 for the indicated
markers. (B) Quantiﬁcation of CD3, CD4, and CD8 positive cells, ratios of CD4C vs CD8C and TIA1C cells in tissue sections from the tumor and in the irAE lesions from
patients 1 and 2. Numbers were calculated on.
Table 2. Quantiﬁcation of inﬁltrating immune cells in tumor and irAE lesions from
patient 1 and 2.
Marker Patient 1 tumor Patient1 irAE Patient 2 tumor Patient 2 irAE
CD3 952.2 880.1 251.8 241.6
CD4 684.4 484.5 170.8 91
CD8 229.9 264.7 76.6 150.7
FoxP3 92.9 84 n.d. 0.28
PD-1 146.6 150.9 15 12.4
PD-L1 371.3 1107.9 n.d. 146.6
TIA1 65.0 386.42 n.d. 158.4
All numbers represent calculated positive cells per mm2 of digitally analyzed IHC
slides. Cell numbers were counted on whole tissue slides. n.d., not detected
(technical issues were excluded by repeating the staining).
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Figure 3. Analysis of TCR repertoire in tumors and irAE lesions. (A) Next generation sequencing of the complementary determining region 3 (CDR3) of the beta chain of
the TCR was performed. The prevalence (frequency of reads compared to all reads in percent) is compared between inﬂammatory lung tissue (irAE, y-axis) and the tumor
from patient 1. (B) Post-mortem frequency of T cell clones found in different tissues from patient 2. The frequency in the tumor was compared to irAE lesions of the lung
(left panel), meninges (middle panel), and the myocardium (right panel). (C, D) Frequency of T cell clones in patient 3 (C) and patient 4 (D). (E) Analysis of overlap of
sequences between tumor lesions and pneumonitis lesions or PBMCs/lymph node (LN). The prevalence (frequency of reads compared to all reads in percent) is compared
between inﬂammatory lung tissue (irAE, y-axis) and the tumor from patient 1 (left panel), patient 2 (middle panel) and all analyzed patients (right panel). Analysis by one-
way ANOVA,  p < 0.05.
Figure 4. Frequency of tumor and irAE-inﬁltrating T cells in the peripheral blood. (A, B) Prevalence of T cell clones in peripheral blood compared to the metastasis (A) or
pulmonary irAE lesion (B) in patient 1. (C, D) Frequency in percent of T cell clones in the lymph node compared to the frequency in the tumor (C) or the pulmonary lung
lesion (D).
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induce epitope spreading.21,22,26 Epitope spreading could
enhance anti-tumor responses but also the generation of
inﬂammatory complications of checkpoint blockade. Epigenetic
reprogramming of T cells is also possibly involved in a break of
peripheral tolerance towards autoantigens and could support
the development of irAEs. Regulatory T cells can be reprog-
rammed to IL-17 producing cells (TH17 cells) that might
induce or support autoimmune diseases including psoriasis or
autoimmune hepatitis.27
We performed histological analysis for T cell markers in
patient 1 and 2. We found in both patients that more T cells were
activated and the CD4 to CD8 ratio was decreased. The analysis
has clear limitations and while the irAE lesions are both from
lungs, the tumor tissue was obtained from lung (patient 1) or
from the liver (patient 2) with a signiﬁcant different microenvi-
ronment. Moreover, the tumor tissue from patient 1 was nearly
completely necrotic, which precludes spatial analysis between
tumor cells and inﬁltrating immune cells. To understand the
immune inﬁltrates better, histological analysis should be per-
formed on a larger and less heterogeneous sample collection.
Our second important ﬁnding is that tumor-speciﬁc T cells
recirculate via the bloodstream to distant organs (in this case the
lung) which are target organs of irAEs. Recent studies found that
anti-tumor T cells can be identiﬁed in the periphery.16,28 We also
found themost prevalent clones were circulating in the peripheral
blood of patients. This fact could also be taken into account when
trying to further investigate the speciﬁcity of these clonotypes.
Understanding the mechanisms how similar T cell clones are
recirculating to the tumor and organs affected by immune-related
side effects could help to identify a biomarker to early detect tox-
icity in patients undergoing checkpoint blockade.
Taken together, our study shows that there is a signiﬁcant
overlap of T cell clones inﬁltrating tumor lesions and pulmo-
nary irAE lesions. In addition, prevalent clones can also be
found in the peripheral blood. While these ﬁndings are hypoth-
esis generating and can be the basis for future work on the loss
of immune tolerance in patients treated with checkpoint inhibi-
tors, further studies are needed to elucidate exact mechanisms
involved in irAE formation and potential targets to prevent
these important side effects of checkpoint inhibition without
affecting anti-tumor efﬁcacy.
Material and methods
Patients and sample preparation
Ethics approval was obtained from the local ethical committee
to analyze the tissue and blood samples (Ethikkomission
Nordwest- und Zentralschweiz, EK321/10 and UBE 15–106).
Written informed consent was obtained from all patients prior
to the sample collection. PBMCs were isolated by Ficoll density
gradient and genomic DNA was prepared. DNA was isolated
from parafﬁn embedded formalin ﬁxed tissue and sent for TCR
analysis. The DNA content was analyzed by a Nanodrop2000.
TCR sequencing and sample analysis
TCR analysis of tissue and PBMC samples was performed from
isolated DNA. The CDR3 region was ampliﬁed and sequenced
by the immunoSEQ Assay (Adaptive Biotechnologies, Seattle,
WA) as previously described.29 Data analysis was performed
using the immunoSEQ Analyzer (Adaptive Biotechnologies,
Seattle, WA).
Histology and immunohistochemistry
Staining of serial tissue sections was performed with antibodies
against CD3 (clone 2GV6, Ventana), CD4 (clone SP36, Venat-
ana), CD8 (clone SP57, Ventana), FoxP3 (clone SP97, Abcam),
PD-1 (clone NAT105, Ventana), PD-L1 (clone SP263, Ven-
tana), granzyme B (polyclonal, Ventana), perforin (clone
MRQ-23, Ventana) and TIA (clone TIA-1, Biocare Medical)
according to standard protocols. Slides were scanned using a
Philips Ultra Fast Scanner 300 (Philips Digital Pathology Solu-
tions, Hamburg Germany). Digital image analysis was carried
out by a board-certiﬁed pathologist (VHK) using HALOTM
v.2.0.1145.19 (Indica Labs, Corrales, NM 87048, USA). In brief,
digital annotations were placed on strict serial sections of
tumor tissue and the corresponding irAE lesions. Areas of
necrosis and unspeciﬁc staining were excluded. Color deconvo-
lution was used to optimize software recognition of cell nuclei
and the 3,30-diaminobenzidine (DAB) reaction product. Detec-
tion of marker-positive cells was optimized and visually con-
trolled for each marker. Machine learning assisted tissue
classiﬁcation was carried out to eliminate pigment and unspe-
ciﬁc staining where appropriate. Whole slide analysis was per-
formed. Total cell counts and marker-positive cells were
quantiﬁed using the HALOTM cytonuclear algorithm, normal-
ized to tissue area and recorded (Figure S1).
Statistical analysis
Statistical analysis was performed with GraphPad Prism ver-
sion 6.05. Statistical tests are noted in the ﬁgure legends and
p-values <0.05 were considered as statistically signiﬁcant.
Acknowledgments
This work was supported by funding from the Lichtenstein Foundation (to
H.L.), Schoenmakers Foundation (to H.L.), the Goldschmidt-Jacobson
Foundation (to H.L), and the Swiss National Science Foundation
(320030_162575 to AZ). Most importantly, we also thank all the patients
that allowed the use of their material and made this work possible.
References
1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a
common denominator approach to cancer therapy. Cancer Cell.
2015;27(4):450–61. doi:10.1016/j.ccell.2015.03.001. PMID:25858804
2. Chen DS, Mellman I. Elements of cancer immunity and the cancer-
immune set point. Nature. 2017;541(7637):321–30. doi:10.1038/
nature21349. PMID:28102259
3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science.
2015;348(6230):56–61. doi:10.1126/science.aaa8172. PMID:25838373
4. Schumacher TN, Schreiber RD. Neoantigens in cancer immunother-
apy. Science. 2015;348(6230):69–74. doi:10.1126/science.aaa4971.
PMID:25838375
5. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD,
Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined
Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
ONCOIMMUNOLOGY e1386362-5
N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030.
PMID:26027431
6. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE,
Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus
Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med. 2015;373(17):1627–39. doi:10.1056/NEJMoa1507643.
PMID:26412456
7. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddub-
skaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolu-
mab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell
Lung Cancer. N Engl J Med. 2015;373(2):123–35. doi:10.1056/
NEJMoa1504627. PMID:26028407
8. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L,
Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for Recur-
rent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med.
2016;375(19):1856–67. doi:10.1056/NEJMoa1602252. PMID:27718784
9. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang
NJ, Climent MA, Petrylak DP, Choueiri TK, et al. Pembrolizumab as
Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J
Med. 2017;376(11):1015–26. doi:10.1056/NEJMoa1613683.
PMID:28212060
10. Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B,
Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, et al. Pros-
pects for combining targeted and conventional cancer therapy with
immunotherapy. Nat Rev Cancer. 2017;17(5):286–301. doi:10.1038/
nrc.2017.17. PMID:28338065
11. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel
S, Schmidgen MI, Gutzmer R, Utikal JS, G€oppner D, et al. Cutaneous,
gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-
1 therapy. Eur J Cancer. 2016;60:190–209. doi:10.1016/j.
ejca.2016.02.025. PMID:27085692
12. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I,
Schmidgen MI, Gutzmer R, Utikal JS, G€oppner D, et al. Neurological,
respiratory, musculoskeletal, cardiac and ocular side-effects of anti-
PD-1 therapy. Eur J Cancer. 2016;60:210–25. doi:10.1016/j.
ejca.2016.02.024. PMID:27084345
13. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-
Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, et al.
Immune-related adverse events with immune checkpoint blockade: a
comprehensive review. Eur J Cancer. 2016;54:139–48. doi:10.1016/j.
ejca.2015.11.016. PMID:26765102
14. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbon-
nel F, Cauquil C, Chanson P, Collins M, Durrbach A, et al. Manage-
ment of immune checkpoint blockade dysimmune toxicities: a
collaborative position paper. Ann Oncol. 2016;27(4):559–74.
doi:10.1093/annonc/mdv623. PMID:26715621
15. Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, Voe-
geli M, Cathomas G, Zippelius A, Mertz KD. Systemic inﬂammation
in a melanoma patient treated with immune checkpoint inhibitors-an
autopsy study. J Immunother Cancer. 2016;4:13. doi:10.1186/s40425-
016-0117-1. PMID:26981243
16. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S,
Xu W, Harmon S, Giles JR, Wenz B, et al. T-cell invigoration to
tumour burden ratio associated with anti-PD-1 response. Nature.
2017;545(7652):60–5. doi:10.1038/nature22079. PMID:28397821
17. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y,
Hicks M, Puzanov I, Alexander MR, Bloomer TL, et al. Fulminant
Myocarditis with Combination Immune Checkpoint Blockade. N
Engl J Med. 2016;375(18):1749–55. doi:10.1056/NEJMoa1609214.
PMID:27806233
18. Dash P, Fiore-Gartland AJ, Hertz T, Wang GC, Sharma S, Souquette
A, Crawford JC, Clemens EB, Nguyen THO, Kedzierska K, et al.
Quantiﬁable predictive features deﬁne epitope-speciﬁc T cell receptor
repertoires. Nature. 2017;547(7661):89–93. doi:10.1038/nature22383.
PMID:28636592
19. Glanville J, Huang H, Nau A, Hatton O, Wagar LE, Rubelt F, Ji X, Han
A, Krams SM, Pettus C, et al. Identifying speciﬁcity groups in the T
cell receptor repertoire. Nature. 2017;547(7661):94–8. doi:10.1038/
nature22976. PMID:28636589
20. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ,
Tahir SA, Korivi BR, Slack RS, Vence L, et al. Clonal expansion of
CD8 T cells in the systemic circulation precedes development of ipili-
mumab-induced toxicities. Proc Natl Acad Sci U S A. 2016;113
(42):11919–24. doi:10.1073/pnas.1611421113. PMID:27698113
21. Oh DY, Cham J, Zhang L, Fong G, Kwek SS, Klinger M, Faham M,
Fong L. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer
Patients Are Associated with Early Diversiﬁcation of the T-cell Reper-
toire. Cancer Res. 2017;77(6):1322–30. doi:10.1158/0008-5472.CAN-
16-2324. PMID:28031229
22. June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles’
heel of cancer immunotherapy? Nat Med. 2017;23(5):540–7.
doi:10.1038/nm.4321. PMID:28475571
23. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute
rhabdomyolysis with severe polymyositis following ipilimumab-nivo-
lumab treatment in a cancer patient with elevated anti-striated muscle
antibody. J Immunother Cancer. 2016;4:36. doi:10.1186/s40425-016-
0139-8. PMID:27330809
24. L€aubli H, Hench J, Stanczak MA, Heijnen I, Papachristoﬁlou A, Frank
S, Zippelius A, Stenner-Liewen F. Cerebral vasculitis mimicking intra-
cranial metastatic progression of lung cancer during PD-1 blockade. J
Immunother Cancer. 2017;5:46. doi:10.1186/s40425-017-0249-y.
25. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S,
Nichol G, Davis T, Keler T, et al. Autoimmunity in a phase I trial of a
fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal anti-
body with multiple melanoma peptides and Montanide ISA 51 for
patients with resected stages III and IV melanoma. J Clin Oncol.
2005;23(4):741–50. doi:10.1200/JCO.2005.01.128. PMID:15613700
26. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong
L. Diversity of antigen-speciﬁc responses induced in vivo with CTLA-
4 blockade in prostate cancer patients. J Immunol. 2012;189(7):3759–
66. doi:10.4049/jimmunol.1201529. PMID:22956585
27. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic
inﬂammation. Nat Rev Drug Discov. 2012;11(10):763–76.
doi:10.1038/nrd3794. PMID:23023676
28. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prick-
ett TD, Gartner JJ, Crystal JS, Roberts IM, et al. Prospective identiﬁca-
tion of neoantigen-speciﬁc lymphocytes in the peripheral blood of
melanoma patients. Nat Med. 2016;22(4):433–8. doi:10.1038/
nm.4051. PMID:26901407
29. Carlson CS, Emerson RO, Sherwood AM, Desmarais C, Chung MW,
Parsons JM, Steen MS, LaMadrid-Herrmannsfeldt MA, Williamson
DW, Livingston RJ, et al. Using synthetic templates to design an unbi-
ased multiplex PCR assay. Nat Commun. 2013;4:2680. doi:10.1038/
ncomms3680. PMID:24157944
e1386362-6 H. L€AUBLI ET AL.
